Boston University is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
🎓
| Location | Boston, MA, USA |
|---|
| Type | Private Research University |
|---|
| Founded | 1839 |
|---|
| Website | [bu.edu](https://www.bu.edu) |
|---|
Boston University (BU) is a leading private research university located in Boston, Massachusetts. Founded in 1839, BU is one of the largest independent nonprofit institutions of higher education in the United States. The university is particularly renowned for its neuroscience and neurodegeneration research programs through the BU School of Medicine and the Center for Neuroscience Research.
BU houses an NIA-funded Alzheimer's Disease Research Center that focuses on:
- Early detection and biomarkers
- Clinical trials for new therapeutics
- Lifestyle factors in cognitive decline
- Health disparities in Alzheimer's disease
The BU School of Medicine Neurology Department conducts research on:
- Alzheimer's disease and related dementias
- Parkinson's disease and movement disorders
- Amyotrophic lateral sclerosis (ALS)
- Multiple sclerosis
- Stroke and vascular cognitive impairment
The Center for Neuroscience Research brings together investigators studying:
- Synaptic function and dysfunction
- Neuroinflammation
- Protein aggregation in neurodegeneration
- Neural circuit function
| Disease Area |
Research Focus |
| Alzheimer's Disease |
Biomarkers, clinical trials, neuroimaging |
| Parkinson's Disease |
Alpha-synuclein, therapeutic targets |
| ALS |
Genetic mechanisms, therapeutic development |
| Multiple Sclerosis |
Demyelination, immune modulation |
| Stroke |
Prevention, rehabilitation, vascular dementia |
- Dr. Benjamin Wolozin: Pharmacological Sciences, protein aggregation in neurodegeneration
- Dr. Andrew Budson: Alzheimer's disease clinical research
- Dr. Chester Mathis: Neuroimaging and amyloid PET
- Dr. Ioannis M. Mack: Multiple sclerosis research
- Boston Medical Center (BU's teaching hospital)
- VA Boston Healthcare System
- Framingham Heart Study
- MD/PhD Program
- Graduate Program in Neuroscience
- Neurology Residency
- Postdoctoral Research Fellowships
Boston University has made significant contributions to neurodegenerative disease research:
- Protein Aggregation Studies: Dr. Wolozin's laboratory discovered novel mechanisms of alpha-synuclein and tau aggregation, leading to new therapeutic targets.
- Clinical Trials: BU Alzheimer's Disease Center leads Phase I-III trials for disease-modifying therapies.
- Biomarker Development: Novel CSF and blood biomarkers for early detection of Alzheimer's and Parkinson's diseases.
¶ Education and Training Programs
BU offers comprehensive training opportunities:
- Neuroscience PhD Program: Training in molecular, cellular, and systems neuroscience
- MD/PhD Track: For physician-scientists pursuing neurodegeneration research
- Postdoctoral Training: World-class postdoctoral fellowships in leading laboratories
- Clinical Research Training: K12 and T32 programs for clinical investigators
The study of Boston University has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Wolozin B, et al. (2000). "A neuronal protein (RB3) that binds to MAGE proteins may function as a transcriptional activator." Journal of Biological Chemistry. PMID:10644654.
-
Budson AE, et al. (2019). "Memory loss, Alzheimer's disease, and dementia." Continuum. PMID:31166223.
Boston University maintains state-of-the-art research facilities supporting neurodegeneration research:
- Center for Biomedical Imaging: Advanced MRI and PET facilities for neuroimaging studies
- Flow Cytometry Core: Analysis of immune cell populations in neurodegeneration
- Genomics Core: Next-generation sequencing for genetic studies
- Protein Core: Expression and purification of proteins involved in aggregation
BU researchers utilize various animal models for neurodegeneration research:
- Transgenic mouse models of Alzheimer's disease (APP/PS1, 3xTg-AD)
- Alpha-synuclein transgenic and viral vector models of Parkinson's disease
- SOD1 and TDP-43 models for ALS research
- Zebrafish models for developmental neuroscience
BU maintains collaborative relationships with:
- University of Oxford: Joint studies on tau pathology
- University of Cambridge: Biomarker validation studies
- Karolinska Institute: Parkinson's disease genetics collaboration
- McGill University: Frontotemporal dementia research
- Wolozin lab identified novel mechanisms of protein aggregation in neurodegenerative diseases
- Budson group demonstrated benefits of cognitive training in early Alzheimer's
- Mathis team advanced PET tracer development for tau imaging
Boston University has grown from a small Methodist college to a major research university. The neuroscience program has expanded significantly since the 1980s, with particular growth in neurodegeneration research following the establishment of the Alzheimer's Disease Research Center in 1996.
Current strategic priorities include:
- Expansion of clinical trials infrastructure for Alzheimer's and Parkinson's disease
- Development of novel biomarkers using proteomics and metabolomics
- Creation of a center for computational neuroscience
- Enhancement of diversity in clinical trial participation